Chloride channel inhibition improves neuromuscular function under conditions mimicking neuromuscular disorders

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

DOI

Aim: The skeletal muscle Cl channels, the ClC-1 channels, stabilize the resting membrane potential and dampen muscle fibre excitability. This study explored whether ClC-1 inhibition can recover nerve-stimulated force in isolated muscle under conditions of compromised neuromuscular transmission akin to disorders of myasthenia gravis and Lambert–Eaton syndrome. Methods: Nerve-muscle preparations were isolated from rats. Preparations were exposed to pre-or post-synaptic inhibitors (ω-agatoxin, elevated extracellular Mg2+, α-bungarotoxin or tubocurarine). The potential of ClC-1 inhibition (9-AC or reduced extracellular Cl) to recover nerve-stimulated force under these conditions was assessed. Results: ClC-1 inhibition recovered force in both slow-twitch soleus and fast-twitch EDL muscles exposed to 0.2 µmol/L tubocurarine or 3.5 mmol/L Mg2+. Similarly, ClC-1 inhibition recovered force in soleus muscles exposed to α-bungarotoxin or ω-agatoxin. Moreover, the concentrations of tubocurarine and Mg2+ required for reducing force to 50% rose from 0.14 ± 0.02 µmol/L and 4.2 ± 0.2 mmol/L in control muscles to 0.45 ± 0.03 µmol/L and 4.7 ± 0.3 mmol/L in muscles with 9-AC respectively (P <.05, paired T test). Inhibition of acetylcholinesterase (neostigmine) and inhibition of voltage-gated K+ channels (4-AP) relieve symptoms in myasthenia gravis and Lambert–Eaton syndrome, respectively. Neostigmine and 9-AC additively increased the tubocurarine concentration required to reduce nerve-stimulated force to 50% (0.56 ± 0.05 µmol/L with 9-AC and neostigmine) and, similarly, 4-AP and 9-AC additively increased the Mg2+ concentration required to reduce nerve-stimulated force to 50% (6.5 ± 0.2 mmol/L with 9-AC and 4-AP). Conclusion: This study shows that ClC-1 inhibition can improve neuromuscular function in pharmacological models of compromised neuromuscular transmission.

OriginalsprogEngelsk
Artikelnummere13690
TidsskriftActa Physiologica
Vol/bind233
Nummer2
ISSN1748-1708
DOI
StatusUdgivet - okt. 2021

Bibliografisk note

Funding Information:
This study was supported by AP M?ller Foundation, The Lundbeck Foundation and the Faculty of Medical Sciences, University of Aarhus. The technical assistance of Marianne St?rup-Johansen is acknowledged.

Funding Information:
This study was supported by AP Møller Foundation, The Lundbeck Foundation and the Faculty of Medical Sciences, University of Aarhus. The technical assistance of Marianne Stürup‐Johansen is acknowledged.

Publisher Copyright:
© 2021 Scandinavian Physiological Society. Published by John Wiley & Sons Ltd

Se relationer på Aarhus Universitet Citationsformater

ID: 223553332